嘌呤代谢
嘌呤类似物
嘌呤
激酶
脱氧胞苷激酶
腺苷激酶
喷昔洛韦
脱氧甲氧霉素
克拉屈滨
药理学
嘌呤核苷磷酸化酶
生物化学
作用机理
戊抑素
生物
腺苷
化学
腺苷脱氨酶
酶
癌症
遗传学
吉西他滨
脱氧胞苷
病毒
单纯疱疹病毒
体外
作者
Sahil Sharma,Samir Mehndiratta,Sunil Kumar,Jagjeet Singh,Preet Mohinder Singh Bedi,Kunal Nepali
出处
期刊:Recent Patents on Anti-cancer Drug Discovery
[Bentham Science]
日期:2015-09-16
卷期号:10 (3): 308-341
被引量:26
标识
DOI:10.2174/1574892810666150617112230
摘要
Protein kinases constitute one of the largest and most functionally diverse gene families that regulate key cell functions. In past several years, kinase inhibition has emerged as potential anti-cancer drug target. Purine is a priveleged heterocyclic nucleus which exists in the chemical architecture of various bioactive compounds. Numerous reports on the use of purine analogues in the treatment of acute leukemias (thiopurines, pentostatin), as antiviral (acyclovir, penciclovir, ganciclovir), as immunosuppressive (azathioprine), as antitumor (vidarabine), as bronchodilator (theophylline) have been revealed. In the past decade, purine analogues have emerged as significantly potent kinase inhibitors. A fair amount of research has been done and several patents have also been published highlighting the kinase inhibitory action of purines. Caffeine, 2-aminopurine, purvalanol-A, seleciclib, FSBA, adenosine thiol analogue possessing purine as the basic moiety fall under this category. In view of the use of purines for the inhibition of kinases, there is need for compilation of data specifying the prominence of purines in the treatment of cancer through this mechanism. The structure of the potent compounds, their IC50 values, models used and the enzymes/ receptors/ targets involved have been presented in this review. The present compilation covers the patents published entailing the purines as kinase inhibitors and the purine drugs employed in chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI